"Almost 1.4 million patients have moderate heart failure. Thirty percent have an electrical disorder and pacemakers are addressing this problem. But that leaves 70% with a large unmet clinical need. They have a progressive condition and they often end up with end-stage heart failure."
— Donald Rohrbaugh CEO of Sunshine Heart (Sydney, Australia) explaining why his company's C-Pulse implantable aortic cuff heart assist device offers an important intervention bridging the clinical gap between heart failure pacemakers and end-stage therapies, "FDA OKs IDE for trial of C-Pulse in moderate heart failure patients."